Pembrolizumab is FDA-approved for the treatment of several types of cancer including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma, urothelial carcinoma, and certain forms of colorectal cancer, among others. It is also used in some cases of metastatic or unresectable cancer.
